More articles from Volume 34, Issue 1, 2018
An immunohistochemical analysis of angiogenic profile in T1 bladder cancer with concomitant carcinoma “in situ”
Crosstalk between NCAM/FGFR and TGF-beta signalings: an in vitro study and evaluation of human kidney biopsies
Primary sinovial sarcoma of the lung - a case report
Hyperostosis frontalis interna: case report
Proliferation marker Ki-67 in early breast cancer
Article views
Alterations of hormone receptors and HER2 receptors status in HER2 amplified locally advanced breast carcinomas after neoadjuvant therapy with Trastuzumab
Faculty of Medicine Novi Sad, University of Novi Sad , Novi Sad , Serbia
Institute for Oncology of Vojvodina , Sremska Kamenica , Serbia
Faculty of Medicine Novi Sad, University of Novi Sad , Novi Sad , Serbia
Institute for Oncology of Vojvodina , Sremska Kamenica , Serbia
Faculty of Medicine Novi Sad, University of Novi Sad , Novi Sad , Serbia
Institute for Oncology of Vojvodina , Sremska Kamenica , Serbia
Faculty of Medicine Novi Sad, University of Novi Sad , Novi Sad , Serbia
Institute for Oncology of Vojvodina , Sremska Kamenica , Serbia
Faculty of Medicine Novi Sad, University of Novi Sad , Novi Sad , Serbia
Institute for Pulmonary Diseases of Vojvodina , Sremska Kamenica , Serbia
General Hospital Sombor , Sombor , Serbia
Faculty of Medicine Novi Sad, University of Novi Sad , Novi Sad , Serbia
Institute for Oncology of Vojvodina , Sremska Kamenica , Serbia
Published: 01.04.2018.
Volume 34, Issue 1 (2018)
pp. 18-19;
Abstract
Aim: The aim of our study was to evaluate status of estrogen and progesteron hormone receptors (ER and PR), and HER2 receptors in diagnostic core biopsy specimens, compared to surgical resection specimens of the same patients after NAC regimens all including trastuzumab. Introduction: Neoadjuvant chemotherapy (NAC) is associated with phenotypic alteration in breast carcinoma, especially with the change of molecular phenotype through the modulation of hormone and HER2 receptors expression. Material and Methods: The study included 35 patients with HER2-amplified locally advanced breast carcinoma that were treated with NAC regimens that included trastuzumab, and which had receptors status determined on pre-NAC core biopsy, and on surgical specimen after the completion of the therapy. Results: Pathological complete response (pCR) was observed in 4 cases (11.4%), while partial response to therapy was noted in 31 cases (88.6%). Invasive breast carcinoma of no special type (NST) was the most common histological type in 27 cases (87.1%), while the most common histological grade (HG) was HG3 in 27 cases (87.1%). There were no noted changes in histological type or grade of the carcinoma. The rates of ER and PR receptors positivity on diagnostic core biopsy compared to post-NAC surgical resection specimens were 61.29% to 67.74% and 48.39% to 64,52%, respectively. HER2 receptors status changed from positive to negative in 2 cases (6,45%). Conclusion: Changes in status of the receptors in breast carcinoma after NAC is significant due to implications in tailored therapy approach, and subsequent modification of adjuvant therapy regimens.
Keywords
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Article metrics
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
